Meijin Energy eyes restructuring investment in Yangtze Medicine

Shanxi Meijin Energy (SZSE:000723) announced its intention to participate in the restructuring investment of Yangtze Medicine Holdings, which is currently undergoing pre-restructuring. At its 32nd meeting of the 10th Board of Directors, the company approved the submission of an investment proposal to the temporary administrator of Yangtze Medicine, with all nine attending directors voting in favor. Meijin Energy will participate in the restructuring as part of a consortium that includes Sichuan Capital Market Relief and Development Equity Investment Fund Partnership, Jiaqiang (Shanghai) Consulting, Zhejiang Orient Star Investment Management, and Beijing Zhonghan Orient Technology Development. The company's decision is based on its development needs and industry advantages.